There have been improvements in combination antiretroviral therapy (cART) over the past 15 years. The aim of this analysis was to assess whether improvements in ART have resulted in improvements in surrogates of HIV outcome.
Methods
Patients in the Australian HIV Observational Database who initiated treatment using mono/duo therapy prior to 1996, or using cART from 1996 onwards, were included in the analysis. Patients were stratified by era of ART initiation. Median changes in CD4+ T-cell count and the proportion of patients with detectable HIV viral load (>400 copies/ml) were calculated over the first 4 years of treatment. Probabilities of treatment switch were estimated using the Kaplan-Meier method.
Results
A total of 2,753 patients were included in the analysis: 28% initiated treatment <1996 using mono/duo therapy and 72% initiated treatment ≥1996 using cART (30% 1996–1999, 12% 2000–2003, 11% 2004–2007 and 19% ≥2008). Overall CD4+ T-cell count response improved by later era of initiation (P<0.001), although 2000–2003 CD4+ T-cell count response was less than that for 1996– 1999 (P=0.007). The average proportion with detectable viral load from 2 to 4 years post-treatment commencement by era was: <1996 mono/duo 0.69 (0.67–0.71), 1996–1999 cART 0.29 (0.28–0.30), 2000–2003 cART 0.22 (0.20–0.24), 2004–2007 cART 0.09 (0.07–0.10) and ≥2008 cART 0.04 (0.03–0.05). Probability of treatment switch at 4 years after initiation decreased from 53% in 1996–1999 to 29% after 2008 (P<0.001).
Conclusions
Across the five time-periods examined, there have been incremental improvements for patients initiated on cART, as measured by overall response (viral load and CD4+ T-cell count) and also increased durability of first-line ART regimens.
References
1.
BoydM.A.Improvements in antiretroviral therapy outcomes over calendar time.Curr Opin HIV AIDS. 2009; 4: 194–199.
2.
WilligJ.H., AbromsS., WestfallA.O.Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.AIDS2008; 22: 1951–1960.
3.
ParientiJ.J., BangsbergD.R., VerdonR., GardnerE.M.Better adherence with once-daily antiretroviral regimens: a meta-analysis.Clin Infect Dis2009; 48: 484–488.
4.
LlibreJ.M., ClotetB.Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment.AIDS Rev2012; 14: 168–178.
5.
BartlettJ.A., FathM.J., DemasiR.An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.AIDS2006; 20: 2051–2064.
6.
RobertsonG.R., GrantD.M., Piquette-MillerM.Pharmacogenetics of pharmacoecology: which route to personalized medicine?Clin Pharmacol Ther2009; 85: 343–348.
7.
PhillipsA.N., StaszewskiS., WeberR.HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.JAMA2001; 286: 2560–2567.
8.
BartP.A., RizzardiG.P., TambussiG.Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.AIDS2000; 14: 1887–1897.
9.
FriedenT.R., Das-DouglasM., KellermanS.E., HenningK.J.Applying public health principles to the HIV epidemic.N Engl J Med2005; 353: 2397–2402.
10.
MarconiV.C., GranditsG.A., WeintrobA.C.Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study.AIDS Res Ther2010; 7: 14.
HammerS.M., SaagM.S., SchechterM.Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.JAMA2006; 296: 827–843.
WrightS.T., PetoumenosK., BoydM.Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience.HIV Med2013; 14: 208–216.
15.
EggerM., MayM., CheneG.Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.Lancet2002; 360: 119–129.
16.
HughesR.A., SterneJ.A., WalshJ.Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.HIV Med2011; 12: 583–593.
17.
TorianL.V., XiaQ.Achievement and maintenance of viral suppression in persons newly diagnosed with HIV, New York City, 2006-2009: using population surveillance data to measure the treatment part of “test and treat”. J Acquir Immune Defic Syndr2013; 63: 379–386.
18.
BartlettJ.A., JohnsonJ., HerreraG.Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudine.J Acquir Immune Defic Syndr2006; 43: 284–292.
19.
MayM.T., SterneJ.A., CostagliolaD.HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.Lancet2006; 368: 451–458.
20.
The Australian HIV Observational Database.Rates of combination antiretroviral treatment change in Australia, 1997–2000.HIV Med2002; 3: 28–36.
21.
FischlM.A., RichmanD.D., HansenN.The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.Ann Intern Med1990; 112: 727–737.
22.
StaszewskiS., MillerV., SabinC.Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.AIDS1999; 13: 951–956.
23.
LiT.S., TubianaR., KatlamaC., CalvezV., Ait MohandH., AutranB.Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease.Lancet1998; 351: 1682–1686.
24.
OrtizR., DejesusE., KhanlouH.Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.AIDS2008; 22: 1389–1397.
25.
GallantJ.E., DeJesusE., ArribasJ.R.Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.N Engl J Med2006; 354: 251–260.
26.
DavidsonI., BeardsellH., SmithB.The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.Antiviral Res2010; 86: 227–229.
27.
HammerS.M., SaagM.S., SchechterM.Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society–USA panel.Top HIV Med2006; 14: 827–843.
FalsterK., GelgorL., ShaikA.Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment.Sex Health2008; 5: 141–154.
30.
MillerW.C., PowersK.A., SmithM.K., CohenM.S.Community viral load as a measure for assessment of HIV treatment as prevention.Lancet Infect Dis2013; 13: 459–464.
31.
XiaQ., WiewelE.W., TorianL.V.Revisiting the methodology of measuring HIV community viral load.J Acquir Immune Defic Syndr2013; 63: e82–e84.
32.
LawM.G., WoolleyI., TempletonD.J.Trends in detectable viral load by calendar year in the Australian HIV observational database.J Int AIDS Soc2011; 14: 10.
